These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29341281)

  • 1. Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?
    Tsai HH
    Aliment Pharmacol Ther; 2018 Feb; 47(4):539-540. PubMed ID: 29341281
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.
    Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2018 Feb; 47(4):540-541. PubMed ID: 29341277
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.
    Le Berre C; Loeuille D; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):794-796. PubMed ID: 30114486
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative Colitis.
    Hilley P; Gilmore R; Srinivasan A; Choy M; De Cruz P
    Inflamm Bowel Dis; 2021 Aug; 27(9):e105-e106. PubMed ID: 33999191
    [No Abstract]   [Full Text] [Related]  

  • 5. Current and emerging biologics for ulcerative colitis.
    Park SC; Jeen YT
    Gut Liver; 2015 Jan; 9(1):18-27. PubMed ID: 25547087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia.
    Lo SW; Connell W; Kamm MA; Lust M; Wright EK
    Aliment Pharmacol Ther; 2021 Aug; 54(4):532-533. PubMed ID: 34331806
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis.
    Ng AC
    J Crohns Colitis; 2021 Oct; 15(10):1774. PubMed ID: 33822914
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?
    Honap S; Pavlidis P; Irving PM
    Aliment Pharmacol Ther; 2021 Aug; 54(3):341-342. PubMed ID: 34236096
    [No Abstract]   [Full Text] [Related]  

  • 9. Rapid Onset of Tofacitinib Induction Therapy for the Treatment of Ulcerative Colitis.
    Griller N; Cohen L
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1213. PubMed ID: 31003697
    [No Abstract]   [Full Text] [Related]  

  • 10. Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.
    Esfahani K; Hudson M; Batist G
    N Engl J Med; 2020 Jun; 382(24):2374-2375. PubMed ID: 32521140
    [No Abstract]   [Full Text] [Related]  

  • 11. IBD: Tofacitinib effective in ulcerative colitis.
    Bradley CA
    Nat Rev Gastroenterol Hepatol; 2017 Jul; 14(7):388. PubMed ID: 28513630
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib.
    Tassone D; Singh S; Sheng Ding N
    Aliment Pharmacol Ther; 2021 Jul; 54(2):206-207. PubMed ID: 34170531
    [No Abstract]   [Full Text] [Related]  

  • 13. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
    Teixeira FV; Damião AOMC; Kotze PG
    Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice.
    Kotze PG; Teixeira FV; Damião AOMC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1208-1209. PubMed ID: 32424919
    [No Abstract]   [Full Text] [Related]  

  • 15. Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Healey P
    J Crohns Colitis; 2016 Nov; 10(11):1310-1315. PubMed ID: 27194530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply.
    Sandborn WJ; Panés J; Sands BE; Reinisch W; Su C; Lawendy N; Koram N; Fan H; Jones TV; Modesto I; Quirk D; Danese S
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1209-1210. PubMed ID: 32424928
    [No Abstract]   [Full Text] [Related]  

  • 17. Tofacitinib for the treatment of ulcerative colitis.
    Izzo R; Bevivino G; Monteleone G
    Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?
    Guillo L; Peyrin-Biroulet L; Louis E
    J Crohns Colitis; 2021 Jul; 15(7):1087-1088. PubMed ID: 33619541
    [No Abstract]   [Full Text] [Related]  

  • 19. Tofacitinib in ulcerative colitis.
    Archer TP; Moran GW; Ghosh S
    Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.